Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/30164
Type
ArticleCopyright
Restricted access
Collections
- INI - Artigos de Periódicos [3384]
Metadata
Show full item record
LONG-TERM EFFICACY AND SAFETY OF THE HIV INTEGRASE INHIBITOR RALTEGRAVIR IN PATIENTS WITH LIMITED TREATMENT OPTIONS IN A PHASE II STUDY
Author
Affilliation
Universitat de Barcelona. Barcelona, España.
Hôpital Pitié-Salpêtriére. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of North Carolina. Chapel Hill, NC, USA.
Istituto Scientifico San Raffaele. Milano, Italia.
Hôpital Paul Brousse. Villejuif, France
New York University. School of Medicine. New York, USA.
Percepticore, LLC. Doylestown, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Hôpital Pitié-Salpêtriére. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
University of North Carolina. Chapel Hill, NC, USA.
Istituto Scientifico San Raffaele. Milano, Italia.
Hôpital Paul Brousse. Villejuif, France
New York University. School of Medicine. New York, USA.
Percepticore, LLC. Doylestown, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Abstract
Raltegravir in combination therapy has demonstrated potent suppression of HIV-1 with a favorable safety profile. This report provides 96-week efficacy and safety data from Protocol 005, a Phase II study.
Share